Strata Critical Medical, Inc. Q2 2026 Earnings Recap

The stock gained 5.4% after reporting better-than-expected growth in the clinical business, driven by strong 23.8% sequential growth in Transplant Clinical revenue and expanding gross margins, which outweighed softness in the Logistics segment.

Key Takeaways

• Clinical revenue increased 15.1% sequentially on an organic basis, fueled by 23.8% growth in Transplant Clinical services.
• Clinical gross margins improved to 26.1% in Q2 from 25% in Q1, enhancing overall profitability.
• Logistics revenue faced headwinds due to significantly reduced flying volumes with one nonexclusive customer, impacting about 3% of segment revenue; volume reduction expected to impact full Q3 before recovery.
• Operating cash flow was $5.7 million with free cash flow of $2.9 million, marking the second consecutive quarter of positive cash generation.
• Closed three bolt-on acquisitions expanding clinical capabilities and geographic reach, strengthening future growth and margin profile while advancing capital deployment ahead of plan.